XGXiaofeng Gong

Xiaofeng Gong

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Xiaofeng Gong has a total of 21 co-authors. Here are the top co-authors by number of shared publications:

  • Bing Zhao

    State Key Laboratory of Genetics and Development of Complex Phenotypes, School of Pharmaceutical Sciences, Zhongshan Hospital and School of Life Sciences, Fudan University, Shanghai, China

    2 shared publications
  • Aaron Gerald Wang

    Shanghai American School, Shanghai, China

    1 shared publication
  • Chao Tu

    Department of Orthopaedics, The Second Xiangya Hospital of Central South University, Changsha, China

    1 shared publication
  • Chen Yang

    BMF Nano Material Technology Company Limited, Shenzhen, China

    1 shared publication
  • Emmanuel Enoch Dzakah

    Z Lab, bioGenous BIOTECH, Shanghai, China

    1 shared publication
  • Hui Yang

    Institute of Organoid Technology, Kunming Medical University, Kunming, China

    1 shared publication

Latest Publications

  • Modeling Wilms Tumor Development with Multiple-Lineage Human Fetal Kidney Organoids Reveals the Cellular Origin and Specific Drivers of Tumorigenesis

    by Xiaofeng Gong, Qing Li, Zhaoting Xu, Jianchen Peng, Yanming Xu, Quanhui Dai, Songnian Yue, Yangyang Ma, Bing Zhao

    Dysregulation of kidney organogenesis can lead to the development of Wilms tumor, a common pediatric kidney cancer. Although numerous mutations implicated in Wilms tumor have been identified through genomic studies, the cellular origin and driver mutations in Wilms tumor remain unclear because of the lack of human models that preserve the complete lineage diversity of the developing kidney. In this study, we established an in vitro condition to generate three-dimensional human fetal kidney organoids (FekO) phenocopying aspects of in vivo renal cellular heterogeneity and complex organization. FekOs faithfully recapitulated the spatial arrangement of ureteric bud (UB) structures and nephron segments. FekOs could be expanded over long time periods. Screening of clinically relevant mutations in Wilms tumor identified key driver mutations and combinations that result in tumor-like neoplasms. Notably, distinct lineages were isolated from fetal kidney tissues to generate UB organoids and nephron organoids, mapping driver mutations to their specific cellular origins. Together, this model provides insights into how different mutations and their combinations drive Wilms tumorigenesis, providing a scalable platform for advancing human kidney developmental disease research. Significance: Development of a faithful fetal kidney organoid model enables identification of lineage-specific driver mutations of Wilms tumors, bridging kidney development-pediatric cancer gaps and enabling scalable translational studies.

  • Vascularized organoid-on-a-chip for centimeter-scale organoid cultivation

    by Xiaofeng Gong, Chen Yang, Jianchen Peng, Xiao Ding, Hui Yang, Aaron Gerald Wang, Emmanuel Enoch Dzakah, Bing Zhao

    An organoid is a three-dimensional (3D) cell culture model that can reproduce the distinct structure and inherent functionality of certain organs. Neverthe


  • 3D Models of Sarcomas: The Next-generation Tool for Personalized Medicine

    by Ruiling Xu, Ruiqi Chen, Chao Tu, Xiaofeng Gong, Zhongyue Liu, Lin Mei, Xiaolei Ren, Zhihong Li

    Sarcoma is a complex and heterogeneous cancer that has been difficult to study in vitro. While two-dimensional (2D) cell cultures and mouse models have been the dominant research tools, three-dimensional (3D) culture systems such as organoids have emerged as promising alternatives. In this review, we discuss recent developments in sarcoma organoid culture, with a focus on their potential as tools for drug screening and biobanking. We also highlight the ways in which sarcoma organoids have been used to investigate the mechanisms of gene regulation, drug resistance, metastasis, and immune interactions. Sarcoma organoids have shown to retain characteristics of in vivo biology within an in vitro system, making them a more representative model for sarcoma research. Our review suggests that sarcoma organoids offer a potential path forward for translational research in this field and may provide a platform for developing personalized therapies for sarcoma patients.